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Objectives The purpose of this study was to evaluate independent associations of high-density lipoprotein cholesterol
(HDL-C) and particle (HDL-P) concentrations with carotid intima-media thickness (cIMT) and incident coronary
heart disease (CHD).
Background HDL-C is inversely related to CHD, and also to triglycerides, low-density lipoprotein particles (LDL-P), and related
metabolic risk. HDL-P associations with CHD may be partially independent of these factors.
Methods In a multiethnic study of 5,598 men and women ages 45 to 84 years old, without baseline CHD, excluding sub-
jects on lipid-lowering medications, triglycerides 400 mg/dl, or missing values, we evaluated associations of
HDL-C and nuclear magnetic resonance spectroscopy-measured HDL-P with cIMT and incident CHD (myocardial
infarction, CHD death, and angina, n  227 events; mean 6.0 years follow-up). All models were adjusted for
age, sex, ethnicity, hypertension, and smoking.
Results HDL-C and HDL-P correlated with each other (  0.69) and LDL-P (  0.38, 0.25, respectively, p  0.05
for all). For (1 SD) higher HDL-C (15 mg/dl) or HDL-P (6.64 mol/l), cIMT differences were  26.1 (95% confi-
dence interval [CI]: 34.7 to 17.4) m and 30.1 (95% CI: 38.8 to  21.4) m, and CHD hazard ratios
were 0.74 (95% CI: 0.63 to 0.88) and 0.70 (95% CI: 0.59 to 0.82), respectively. Adjusted for each other and
LDL-P, HDL-C was no longer associated with cIMT (2.3; 95% CI:  9.5 to 14.2 m) or CHD (0.97; 95% CI: 0.77
to 1.22), but HDL-P remained independently associated with cIMT (22.2; 95% CI:  33.8 to 10.6 m) and
CHD (0.75; 95% CI: 0.61 to 0.93). Interactions by sex, ethnicity, diabetes, and high-sensitivity C-reactive protein
were not significant.
Conclusions Adjusting for each other and LDL-P substantially attenuated associations of HDL-C, but not HDL-P, with cIMT and
CHD. Potential confounding by related lipids or lipoproteins should be carefully considered when evaluating HDL-
related risk. (J Am Coll Cardiol 2012;60:508–16) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.060There is great interest in raising levels of high-density
lipoprotein cholesterol (HDL-C), given its well-established
inverse association with atherosclerosis and coronary heart
disease (CHD) (1). However, quantification of HDL-C,
the cholesterol carried by HDL particles (HDL-P), may not
fully capture HDL-related risk (1,2). For example, some
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August 7, 2012:508–16 HDL Cholesterol, Particles, and Atherosclerotic CHDing cardiovascular disease (CVD) events (5,6) or atherosclerosis
(7) have also fueled interest in alternative indexes of HDL
quantity (i.e., HDL-P or apolipoprotein A-I [apo A-I]) or
possibly HDL “quality,” such as, particle size, subclass distribution
(8), or various measures of HDL functionality (2).
The association of HDL-C with CHD risk is compli-
ated by the inverse association of HDL-C with triglycerides,
nsulin resistance, obesity, high-sensitivity C-reactive pro-
ein (hsCRP), and atherogenic lipoprotein particles, (i.e.,
polipoprotein B [apo B] and LDL particle [LDL-P]
oncentration) (1). Recent reports showed that adjusting for
po B and apo A-I abolished the inverse association of
DL-C with CHD risk (9), but HDL-P remained in-
ersely associated with CHD, adjusted for apo B, triglycer-
des, and HDL particle size (10). Therefore, we hypothe-
ized that HDL-C associations with carotid intima-media
hickness (cIMT) and incident CHD events partly reflect
orrelated lipid, apolipoprotein, or lipoprotein concentra-
ions, particularly LDL-P, but that HDL-P associations are
ess affected by these metabolic risk factors, including
DL-C. Because HDL functionality has been reported to
e altered in diabetes (11,12), with inflammation (13), by
thnicity (14), or sex (15), we also evaluated potential
nteractions by baseline diabetes, hsCRP, sex, and ethnicity.
ethods
articipants and risk factor measurement. Participants
ligible for the present study were 6,814 men and women
nrolled at baseline (2000 to 2002) in the National Heart,
ung, and Blood Institute (NHLBI) sponsored multicenter
ommunity-based cohort, Multi-Ethnic Study of Athero-
clerosis (MESA), the design and objectives of which have
een previously described (16). Briefly, MESA participants
ere community-dwelling men and women 45 to 84 years
ld, of African American, Hispanic, white, and Chinese
merican ethnicity. Baseline exclusion criteria included
elf-reported CVD (heart attack, angina, coronary, or any
ther arterial revascularization procedure; pacemaker or
efibrillator implantation; valve replacement; heart failure or
erebrovascular disease), pregnancy, cancer, cognitive im-
airment, or weight 136 kg. The present study excluded
articipants with baseline lipid-lowering medication use
n  1,100), triglycerides 400 mg/dl (n  57), or missing
alues for lipid-lowering medication use, HDL-C, HDL-P,
r smoking (n  59). Of the remaining 5,598 participants,
IMT was missing for 57 (1.0%), and incident CHD data
as missing for 1, leaving 5,541 participants for the cIMT
nalyses and 5,597 participants for the CHD analyses.
articipants provided informed written consent at their field
enters. The study was approved by the institutional review
oards of the participating institutions and the University of
ittsburgh.
Height, weight, blood pressure, and medications were
ollected at the baseline MESA examination. Smoking was
efined as never, former (smoked 100 cigarettes in life-ime), or current (smoked ciga-
ettes in last 30 days). Hyperten-
ion was defined as systolic blood
ressure 140 mm Hg or dia-
tolic blood pressure 90 mm
g, or self-reported hyperten-
ion and antihypertensive medi-
ation use. Hormone therapy use
as defined as current user (yes/
o). Type 2 diabetes was defined
s fasting glucose 125 mg/dl or
se of antidiabetic medication.
omeostasis model assessment
f insulin resistance (HOMA-
R) was calculated as: insulin
IU/l)  (glucose [mg/dl] 
0.055)/22.5 for those not on an-
tidiabetic medication (17).
Lipid, lipoprotein, and other
laboratory assays. Blood was
drawn after a 12-h fast, and sam-
ples were stored at 70°C. Lip-
ids, insulin, and glucose were
measured at a central laboratory
(Collaborative Studies Clinical Lab-
oratory at Fairview University Med-
ical Center, Minneapolis, Minne-
sota). Lipids were assayed on
thawed ethylenediaminetetraacetic
acid plasma within 2 weeks of
the sample collection, using Centers for Disease Control
Prevention/NHLBI standards. HDL-C was measured us-
ing the cholesterol oxidase method (Roche Diagnostics,
Indianapolis, Indiana) after precipitation of non–HDL-C
with magnesium/dextran (coefficient of variation 2.9%).
LDL-C was calculated using the Friedewald equation (18).
Plasma lipoprotein particle concentrations were measured at
LipoScience, Inc. (Raleigh, North Carolina) by nuclear
magnetic resonance (NMR) spectroscopy using the
LipoProfile-3 algorithm. HDL-P and LDL-P (coefficient
of variation 4%) are the sums of the particle concentra-
tions of their respective subclasses, which are quantified
based on particle size using the amplitudes of their lipid
methyl group NMR signals, and mean particle sizes are the
weighted average of related subclasses (19).
Endpoints. Carotid atherosclerosis was measured using
high-resolution B-mode ultrasound as previously described
for the Cardiovascular Health Study (20). cIMT was cal-
culated from maximal thickness measured at 8 sites (right
and left, near and far walls of the common and internal
carotid arteries) as previously described (21). Incident CHD
events (myocardial infarction, CHD death, resuscitated
cardiac arrest, or definite or probable angina (followed by
revascularization) were ascertained and adjudicated for
Abbreviations
and Acronyms
apo A-I  apolipoprotein A-I
apo B  apolipoprotein B
CHD  coronary heart
disease
CI  confidence interval
cIMT  carotid intima-
media thickness
CVD  cardiovascular
disease
HDL-C  high-density
lipoprotein cholesterol
HDL-P  high-density
lipoprotein particles
HOMA-IR  homeostasis
model of insulin resistance
HR  hazard ratio
hsCRP  high-sensitivity
C-reactive protein
LDL-C  low-density
lipoprotein cholesterol
LDL-P  low-density
lipoprotein particles
NHLBI  National Heart,
Lung, and Blood Institute
NMR  nuclear magnetic
resonanceMESA as previously described (22).
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HDL Cholesterol, Particles, and Atherosclerotic CHD August 7, 2012:508–16Hypotheses were also tested using secondary endpoints
of: 1) “hard” CHD, which excluded angina; 2) “all CVD,”
which was “all CHD” plus stroke, stroke death, other
atherosclerotic death, or other CVD death; 3) “hard” CVD,
which included “hard CHD” plus stroke and stroke death;
and 4) cIMT considered separately for the common versus
the internal (more susceptible to plaque) carotid artery.
Statistical analysis. Analyses were performed using SAS
version 9.2 (SAS Institute, Cary, North Carolina). Two-
tailed p values 0.05 were considered significant. Spearman-
rank correlations were adjusted for age, sex, and ethnicity.
HDL-C and HDL-P were analyzed as continuous variables
(results reported per 1-SD increment) or categorized as
tertiles or quartiles. Triglycerides were log-transformed.
Associations with cIMT were modeled using analysis of
covariance and linear regression, and with incident CHD
events using Cox proportional hazards regression. All mod-
els were adjusted for a base set of covariates: age, sex,
ethnicity, hypertension, and smoking. A p value for linear
trend was calculated using contrasts. Hypothesized differ-
ences by sex, ethnicity, diabetes, and hsCRP were tested by
including interaction terms with HDL-C and HDL-P for
each of the models, with the main effect included in the
model. Sensitivity analyses included excluding hormone
therapy users (n  837), stratifying by sex, and also testing
hypotheses using the previously described secondary end-
points (i.e., hard CHD, all CVD, hard CVD, internal
carotid artery cIMT, and common carotid artery cIMT).
To illustrate multivariable regression results, a stratified
analysis was used to calculate adjusted mean cIMT for
HDL-C tertiles within HDL-P tertiles, and then further
stratified by above and/or below median LDL-P. Tertiles
(HDL-C and HDL-P) were used rather than quartiles to
allow for a sufficient number of individuals in discordant
cells (i.e., high HDL-C/low HDL-P or low HDL-C/high
HDL-P). Finally, we sought to replicate a report of an
increased risk of CHD for very high HDL-C (80 mg/dl)
relative to low HDL-C (40 mg/dl) in adjusted models (9),
and also evaluated CHD risk for very high versus low
HDL-P, using the corresponding 95th and 25th percentiles
of HDL-P (45.7 and 29 mol/l).
Results
Study participants were multiethnic men and women 45 to
84 years old from MESA, without baseline clinical CVD or
lipid-lowering medication use (Table 1). HDL-C and
HDL-P concentrations were positively correlated (Fig. 1).
HDL-C and HDL-P were inversely correlated with
LDL-C, weakly (0.08,0.13, respectively), and with
DL-P, more strongly (0.38,0.25), and with other
metabolic risk factors (e.g., small LDL-P, triglycerides,
body mass index, waist circumference, and HOMA-IR),
but for all, correlations were stronger for HDL-C than for
HDL-P (Table 2). (LDL-C and LDL-P. Positive associations of LDL-C and
LDL-P with cIMT showing that CVD events in MESA
have been published (21,23), and when LDL-P and
LDL-C differed, associations were stronger for LDL-P
(23). In our study, adjusted for base covariates, the cIMT
difference per 1-SD increment was 28.8 (95% confidence
interval [CI]: 13.4 to 44.3) m for LDL-C and 36.5 (95%
CI: 20.8 to 52.1) m for LDL-P. The hazard ratios (HRs)
or CHD per 1-SD increment were 1.24 (95% CI: 1.09 to
.42) for LDL-C and 1.29 (95% CI: 1.13 to 1.47) for
DL-P, adjusted for base covariates. LDL-C and LDL-P
ach remained associated (p  0.05) with cIMT and
ncident CHD in the models reported in the tables, which
ere also adjusted for HDL-P, HDL-C, or both.
ssociations with carotid atherosclerosis. Adjusted for
ase covariates (age, sex, ethnicity, hypertension, and smok-
ng), mean cIMT was lower with higher quartiles of HDL-C
Characteristics of MESA Participantsin Study (n  5,598), 2000 o 2002Table 1 Characteristics of MESA Participantsin Study (n  5,598), 2000 to 2002
Age, yrs 61.5 10.3
Women, % 52.9
Ethnicity, %
White 37.6
Chinese American 12.1
African American 27.7
Hispanic 22.7
Body mass index, kg/m2 28.2 5.5
Waist circumference, cm 97.6 14.4
Smoker, %
Current 13.5
Former 36.0
Hypertension, % 41.3
Diabetes, % 10.7
Carotid intima-media thickness, m 946 339
Lipids, mg/dl
HDL-C 51.2 15
LDL-C 119.6 31.3
Total cholesterol 195.8 34.6
Triglycerides 124.5 64.8
Lipoprotein particle concentrations
HDL-P, mol/l
Total 33.8 6.6
Large 6.1 3.5
Medium 13.4 6.8
Small 14.3 5.6
LDL-P, nmol/l
Total 1,261 342
Large 607 253
Small 524 381
IDL-P 130.5 98.5
Lipoprotein particle size (nm)
LDL 20.8 0.6
HDL 9.3 0.5
Values are mean  SD or %.
HDL  high-density lipoprotein; HDL-C  HDL cholesterol; HDL-P: HDL particles; IDL-P 
intermediate-density lipoprotein particles; LDL low-density lipoprotein; LDL-C LDL cholesterol,
DL-P  LDL particles; MESA  Multi-Ethnic Study of Atherosclerosis.Fig. 2A) or HDL-P (Fig. 2B). The inverse linear associa-
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ing for LDL-P or for HDL-P, and was abolished when
adjusted for both. In contrast, HDL-P remained inversely
associated with cIMT after adjusting for LDL-P, HDL-C,
or both (p for trend 0.05, for all).
Figure 1 Scatterplot of HDL-C by HDL-P
Spearman correlation between high-density lipoprotein cholesterol (HDL-C) (milligra
is   0.69; p  0.0001.     0  women;     1  men.
Spearman Correlations of the Concentrations ofHDL-C and HDL-P P) Among MESA Partic pantsin Study (n  5,598), 2000 to 2002
Table 2
Sp arman Correlati s of he Concentrations of
HDL-C and HDL-P P) Among MESA Participants
in Study (n  5,598), 2000 to 2002
Characteristics HDL-C HDL-P
Mean HDL particle size, nm 0.68 0.34
LDL-C, mg/dl 0.08 0.13
Triglycerides, mg/dl 0.48 0.09
Total cholesterol, mg/dl 0.14 0.12
Large HDL-P, mol/l 0.87 0.53
Medium HDL-P, mol/l 0.45 0.58
Small HDL-P, mol/l 0.28 0.07
Mean LDL-P size, nm 0.69 0.32
LDL-P, nmol/l 0.38 0.25
Large LDL-P, nmol/l 0.53 0.22
Small LDL-P, nmol/l 0.69 0.38
Body mass index, kg/m2 0.26 0.12
Waist circumference, cm 0.27 0.12
HOMA-IR* 0.38 0.16
C-reactive protein, mg/l 0.15 0.05
All correlations (Spearman-rank) are adjusted for age, sex, ethnicity, and all are statistically
significant (p  0.0001). *Calculated for participants reporting no antidiabetic medication
(n  5,157).
HOMA-IR  homeostasis model of insulin resistance; other abbreviations as in Table 1.Additional models are shown in Table 3, which reports
adjusted mean cIMT differences for a 1-SD increment in
HDL-C or HDL-P. Separately, higher HDL-C and
HDL-P were each associated with lower mean cIMT, and
were modestly attenuated by adjusting for LDL-C or
HDL-P size. However, adjusting for LDL-P substantially
attenuated cIMT estimates, more for HDL-C (12.2; 95%
CI: 21.4 to3.1 m) than for HDL-P (20.7; 95% CI:
29.6 to 11.8 m). Further adjustment for LDL-C and
riglycerides had little effect.
In joint models (HDL-C and HDL-P adjusted for
ach other and base covariates [Table 3, lower panel]),
DL-C and HDL-P associations were only mildly
ttenuated by adjusting for LDL-C. However, adjusted
or HDL-P, HDL-C was no longer significantly associ-
ted with cIMT (11.1; 95% CI: 22.7 to 0.42 m),
and became positive, but not statistically significant, in
models that also adjusted for mean HDL size or LDL-P,
with or without LDL-C and triglycerides. Conversely,
HDL-P remained inversely associated with cIMT (22.2;
5% CI: 33.8 to 10.6 m) when adjusted for HDL-C,
and also for LDL-P or HDL size, or LDL-P, LDL-C,
and triglycerides.
To visualize the multivariable model results, Figure 3
shows adjusted mean cIMT for cross-classified tertiles of
HDL-C and HDL-P (Fig. 3A), and further stratified by
r deciliters) and high-density lipoprotein particle (HDL-P) (nanomole per liter)ms pemedian LDL-P (Figs. 3B and C). Power is limited for these
w
(
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groups (e.g., high HDL-C/low HDL-P). Within HDL-P
tertiles, HDL-C was generally not inversely associated with
cIMT (HDL-C trend, p  NS for all) (Fig. 3A). However,
Figure 2
Mean cIMT Across Quartiles of HDL-C or HDL-P,
Before and After Adjusting for LDL-P and Each Other
(n  5,541)
(A) Mean carotid intima-media thickness (cIMT) (micrometers) across HDL-C
quartiles, adjusted for base covariates, p  0.001; adjusted for base covari-
ates plus low-density lipoprotein particle (LDL-P), p  0.01; adjusted for base
covariates plus HDL-P, p  0.051; and adjusted for base covariates plus LDL-P
and HDL-P, p  0.75. (B) Mean cIMT (micrometers) across HDL-P quartiles;
adjusted for base covariates, p  0.0001; adjusted for base covariates plus
LDL-P, p  0.0001; adjusted for base covariates plus HDL-C, p  0.002; and
adjusted for base covariates plus LDL-P and HDL-C, p  0.001. Base covari-
ates (base cov.) are age, sex, ethnicity, hypertension, and smoking. Error bars
are SEs; p values are for linear trend. Abbreviations as in Figure 1.within each HDL-C tertile, each HDL-P was inverselyassociated with cIMT in both low and high HDL-C tertiles
(p trend  0.05 for both). When further stratified by
median LDL-P (Figs. 3B and 3C), trends were generally
not statistically significant, but HDL-C was positively
associated with cIMT within 5 of the 6 HDL-P tertiles,
whereas HDL-P remained inversely associated with cIMT
within 5 of the 6 HDL-C tertiles.
Sensitivity analyses for cIMT associations. Interaction
terms for sex, ethnicity, diabetes status, or hsCRP were not
significant. In sex-stratified models, adjusted for LDL-P
and each other, HDL-C was not inversely associated with
cIMT for women (1.2; 95% CI: 15.0 to 12.7 m) or
men (8.3; 95% CI: 13.4 to 30.1 m), whereas HDL-P
as significantly inversely associated with cIMT for women
17.8; 95% CI:31.4 to4.2 m) and men (27.1; 95%
CI 47.7 to 6.4 m). Evaluated separately, the internal
and common carotid arteries showed similar results to our
combined cIMT measure, although associations were
slightly stronger for the internal carotid artery, which is
more prone to plaque.
Associations with incident coronary heart disease events.
Among the 5,597 participants with incident CHD data, 227
CHD events occurred during a 6.0 1.4 years of follow-up.
The proportionality assumption appeared valid (i.e., inter-
actions of time with HDL-C or HDL-P were not signifi-
cant). CHD risk was reported for quartiles and for a 1-SD
increment in HDL-C and HDL-P, for separate and joint
models (Table 4). Separately, higher HDL-C and HDL-P
were similarly associated with lower CHD risk, adjusted for
base covariates. Adjusting for LDL-C or HDL particle size
had little effect. Adjustment for LDL-P attenuated the
association for HDL-C to a greater extent than for HDL-P.
In joint models (adjusted for HDL-P), HDL-C HRs were
not statistically significant and became weakly positive when
adjusted for LDL-P, LDL-C, and (log) triglycerides. In
contrast, the inverse association of HDL-P with CHD
remained statistically significant when adjusted for HDL-C,
LDL-P, LDL-C, and triglycerides.
Sensitivity analysis for CHD associations. In multivari-
able models, interaction terms for sex, ethnicity, diabetes, or
hsCRP were not statistically significant. Results were sim-
ilar if adjusted for baseline diabetes status, or if current
hormone users were excluded, or if stratified by sex. With
few cases among women (n  66), CHD risk estimates for
women were not statistically significant, but the base
covariate-adjusted HR (95% CI) for (1 SD) higher HDL-C
was 0.81 (95% CI: 0.63 to 1.05) and became 1.00 (95% CI:
0.71 to 1.43) when adjusted for HDL-P and LDL-P,
whereas for HDL-P, the base covariate-adjusted HR of
0.77 (95% CI: 0.59 to 1.00) became 0.81 (95% CI: 0.57 to
1.14) when adjusted for HDL-C and LDL-P. Results were
also similar for the secondary outcomes of all CVD or hard
CHD or hard CVD (Online Table 1).
Finally, we evaluated CHD risk associations at very high
levels of HDL-C and HDL-P. Adjusted for base covariates,
LDL-P, HDL-P, and log-triglycerides, the HR for very
able 1.
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(40 mg/dl) became positive and statistically significant
(HR: 2.59; 95% CI: 1.11 to 6.02). Conversely, adjusted for
base covariates, LDL-P, HDL-C, and log triglycerides, the
HR for analogous very high versus low HDL-P (45.7 vs.
29 mol/l) was 0.50 (95% CI: 0.19 to 1.35).
Discussion
Among multiethnic men and women without clinical CVD
or lipid-lowering medication use at baseline, HDL-C asso-
ciations with cIMT and incident CHD were substantially
attenuated by adjusting for atherogenic lipoproteins, partic-
ularly LDL-P. In contrast, HDL-P associations with cIMT
and incident CHD were relatively unaffected by adjusting
for atherogenic lipoproteins, HDL-C, and mean HDL
particle size. Results were similar for secondary outcomes of
all CVD, and hard CHD or CVD events.
Few studies have evaluated HDL-P associations with
CHD risk, and we know of none that evaluated it jointly
with HDL-C and LDL-P. Low HDL-P levels predicted
CHD death over 18 years of follow-up among men with
metabolic syndrome in the MRFIT (Multiple Risk Factor
Intervention Trial) cohort (24). In EPIC (European Pro-
spective Investigation into Cancer and Nutrition)-Norfolk,
lower HDL-P levels predicted incident events independent
of age, sex, apo B, triglycerides, mean HDL particle size,
smoking, myeloperoxidase, paraoxonase-1, and hsCRP
(10). Lower HDL-P also predicted CVD events among
HIV patients (25). In the VA-HIT (Veterans Affairs
High-Density Lipoprotein Cholesterol Intervention Trial),
lower levels of baseline and on-trial HDL-P predicted
CHD events among men with low HDL-C randomized to
gemfibrozil versus placebo (26). In the large Women’s
Health Study, the inverse association of HDL-P with
incident CVD over an 11-year follow-up was not significant
Predicted Difference in cIMT for a 1-SD GreaterHDL-P Concent ation Among MESA Particip ntsTable 3 Predict d Difference in cIMT for a 1HDL-P Concentration Among MESA
HDL-C and HDL-P in Separate Models, Covariates
Basic model*
Plus LDL-C
Plus HDL size
Plus LDL-P
Plus LDL-P, LDL-C, and (log) TG
Joint Models† of HDL-C, HDL-P, Covariates
Basic model
Plus LDL-C
Plus HDL size
Plus LDL-P
Plus LDL-P, LDL-C, and (log) TG
*Basic model and all substantial models are adjusted for: age, sex, eth
and HDL-P together in the same model.
cIMT  carotid intima-media thickness; other abbreviations as in T(27). However, HDL-P was inversely associated with inci-dent CHD among postmenopausal women in the Women’s
Health Initiative Hormone Trial, adjusted for treatment
arm (28), and the inverse association of HDL-P with cIMT
was statistically significant for women in the present study.
Future studies may help to reconcile these results.
In this study, HDL-C was not inversely associated with
cIMT or CHD after adjusting for LDL-P and HDL-P,
similar to reported attenuation of HDL-C associations
when adjusted for apo B, as an index of atherogenic
lipoproteins, and apo A-I (9). In our study, very high
HDL-C (80 mg/dl) became positively associated with
CHD risk (p  0.05) when adjusted for LDL-P, HDL-P,
and triglycerides, as reported in the IDEAL (Incremental
Decrease in Clinical Endpoints Through Aggressive Lipid
Lowering) study (adjusted for apo B and apo A-I) (9). In
contrast, very high HDL-P (45.7 mol/l) remained
inversely associated with CHD, in models adjusting for
LDL-P, HDL-C, and triglycerides. However, the results of
our study suggest that, adjusted for LDL-P and HDL-P,
HDL-C loses its inverse association with atherosclerotic
CHD across the range of HDL-C, not just at very high
HDL-C.
Potential mechanisms. These results suggest that because
HDL-C, the cholesterol content of HDL, varies inversely
with triglycerides, LDL-P, or apo B, and other metabolic
risk factors, the risk attributed to HDL-C might come from
several sources other than low levels of particles (i.e.,
HDL-P). In contrast, HDL-P remained inversely associ-
ated with atherosclerotic risk relatively independently of
both atherogenic lipoprotein levels, and its own cholesterol
content (i.e., HDL-C). More HDL-P might equal higher
reverse cholesterol transport capacity. Cholesterol efflux, an
index of the capacity of HDL for reverse cholesterol
transport, was inversely correlated with cIMT and angio-
graphic coronary disease independent of HDL-C, and
C or5,541), 2000 to 2002Greater HDL-C or
icipants (n  5,541), 2000 to 2002
Difference (95% CI) in cIMT (m)
DL-C (SD 15 mg/dl) HDL-P (SD 6.64 mol/l)
6.1 (34.7 to17.4) 30.1 (38.8 to21.4)
2.7 (31.4 to14.1) 25.5 (34.2 to16.7)
9.3 (31.2 to7.4) 25.5 (34.6 to16.3)
2.2 (21.4 to3.1) 20.7 (29.6 to11.8)
3.9 (23.9 to3.9) 21.6 (30.5 to12.7)
11.1 (22.7 to 0.42) 22.7 (34.3 to11.0)
10.9 (22.4 to 0.6) 18.2 (29.8 to6.5)
4.9 (11.0 to 20.8) 27.9 (40.1 to15.8)
2.3 (9.5 to 14.2) 22.2 (33.8 to10.6)
5.7 (8.2 to 19.7) 25.2 (37.6 to12.8)
ypertension, and smoking. †Joint models report estimates with HDL-CHDL-(n -SD
Part
H
2
2
1
1
1


nicity, hcholesterol efflux was also associated with higher levels of
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HDL-C (29). Furthermore, in a study of diabetic patients,
cholesterol efflux was positively associated with total
HDL-P but not with HDL-C or apo A-I (30). Antiathero-
genic benefits of higher HDL-P (antioxidation, anti-
inflammation, and so on) may also be related to the protein
or other cargo of HDL (e.g., apo A-I, paraoxonase-1,
myeloperoxidase) rather than to its cholesterol cargo (1,2).
In EPIC-Norfolk, the HDL-associated antioxidant
paroxonase-1 was more strongly correlated with HDL-P
than with HDL-C or apo A-I (10). However, given the
complexity of HDL, many potential mechanisms require
further investigation (2).
Therapeutic interventions. Lifestyle and pharmacological
interventions to increase low HDL-C have been reviewed
elsewhere (31), but few studies have evaluated intervention
effects on HDL-P compared with HDL-C. A few studies
have reported that HDL-C and HDL-P were both higher
with hormone therapy (28) and alcohol intake (32). Active
smokers had lower levels of both HDL-C and HDL-P (33),
and both increased with smoking cessation in a recent
randomized clinical trial (34). The limited existing data
suggested that physical activity (35) and diet and/or exercise
interventions might increase HDL-C but not HDL-P (36),
which would occur if large cholesterol-rich particles in-
creased at the expense of smaller particles.
Niacin also raised HDL-C with little effect on HDL-P
(37). Torcetrapib reportedly raised HDL-P by only 1%
despite a 53% increase in HDL-C (38). In contrast,
gemfibrozil increased HDL-P more than HDL-C in VA-
HIT, and as noted, on-treatment HDL-P predicted lower
CHD events (26). Statins also increased HDL-P more than
HDL-C, as well as decreasing LDL-P less than LDL-C
(39). Among diabetic individuals, effects of vitamin E intake
on HDL function (i.e., cholesterol efflux) differed by haptoglobin
genotype, increasing it for Hp2-2 and decreasing it for Hp
2-1 (12). Whether effects on HDL-P levels would parallel
these effects is unknown. Additional research is needed to
quantify differential effects of pharmacological interventions
as well as types of diet, omega-3 fatty acids, haptoglobin
genotype (12), and other influences on HDL in relation to
outcomes.
Potential implications. These results showed that associ-
ations of HDL-C with CHD risk might be partially due to
metabolic correlations with atherogenic lipoprotein concen-
trations. In contrast, associations of HDL-P with CHD risk
were substantially independent of atherogenic lipoprotein
concentrations and of HDL-C. HDL-C is one measured
parameter of HDL. It might be important to assess param-
eters other than HDL-C in clinical trials of interventions to
raise HDL. HDL-P might be an alternative to HDL-C as
a marker of HDL-related cardiovascular risk, if these findings
are confirmed in other studies and found to be cost-effective.
Potential limitations. These results, although robust, were
observational, did not prove causality, and might be subjectFigure 3
Mean cIMT (micrometers) by Joint Tertiles of
HDL-C and HDL-P, Entire Group, and Stratified
by Median LDL-P (1236.5 nmol/l)
All models adjusted for base covariates. HDL-C tertiles: low HDL-C (42
mg/dl), medium HDL-C (43–54 mg/dl), high HDL-C: (55 mg/dl). HDL-P ter-
tiles: low HDL-P (30.5 mol/l), medium HDL-P (30.6–36.1 mol/l), high
HDL-P: (36.2 mol/l). (A) Entire study sample. p  NS for HDL-C trend
within each HDL-P tertile; p  0.05 for HDL-P trend for both low and high
HDL-C tertiles, and p  NS for medium HDL-C tertiles. (B) Participants with
LDL-P below the median. p  NS for HDL-C trend within each HDL-P tertile; and
p  0.06, 0.09, 0.02 for HDL-P trend within HDL-C tertile for low, medium, and
high HDL-C tertiles, respectively. (C) Participants with LDL-P above the median.
Neither HDL-C trends within each HDL-P tertile, nor HDL-P trends within each
HDL-C tertile were significant. Adjusted for base covariates (base cov.): age,
sex, ethnicity, hypertension, and smoking. Error bars are SEs; p values are for
linear trend. Abbreviations as in Figures 1 and 2.to bias and confounding, measurement error, or unmeasured
ls are a
s; othe
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metabolically interrelated (8,11) and statistical modeling in
a large observational study is only one tool to investigate
potential effects of these interrelationships, which warrant
additional metabolic studies. However, despite statistical
adjustment for several correlated lipoproteins, multicol-
linearity was not a problem in this study, as assessed by
variance inflation factors. Apo A-I and apo B are not
currently available in MESA, so their influence could not be
evaluated in the present study. Finally, there were very few
events at the high end of the HDL parameter ranges and
few among women, limiting our ability to evaluate indepen-
dent effects on CHD risk in those groups.
Conclusions
Among multiethnic men and women, associations of
HDL-C with cIMT and incident CHD were substantially
attenuated by adjusting for atherogenic lipoproteins and
HDL-P, whereas HDL-P remained significantly inversely
associated with cIMT and incident CHD, independent of
atherogenic lipoproteins (LDL-P, triglycerides, and
LDL-C) and HDL-C. These results might have implica-
tions both for risk assessment and for evaluation of thera-
peutic interventions, particularly pharmacological interven-
tions that might differentially affect several lipid and
lipoprotein parameters concurrently. Quantitative and met-
abolic interrelationships between lipids and the lipoprotein
particles that carry them should be considered when evalu-
ating associations between single parameters (e.g., HDL-C
Risk of Incident CHD Across Higher HDL-C and HDL-P Quartiles and1-SD Increm t Among MESA Participants (  5,597), Bas line 2Table 4 Risk of I cident CHD A ross Higher HDL-C and HDL-P1-SD Increment Among MESA Participants (n  5,597
HR (95% CI) by HDL-C
Q1: 15–40 Q2: 41–48
Basic model† 1.0 0.67 (0.48–0.94)
Plus LDL-C 1.0 0.64 (0.46,0.89)
Plus HDL size 1.0 0.67 (0.48,0.94)
Plus LDL-P 1.0 0.67 (0.48–0.94)
Plus HDL-P 1.0 0.77 (0.54–1.09)
Plus HDL-PLDL-P 1.0 0.76 (0.54–1.08)
Plus HDL-P, LDL-P, LDL-C, TG 1.0 0.83 (0.57–1.20)
HR (95% CI) by HDL-P
Q1: 14.4–29 Q2: 29.1–33.1
Basic model 1.0 0.79 (0.57–1.08)
Plus LDL-C 1.0 0.81 (0.59–1.12)
Plus HDL size 1.0 0.81 (0.59–1.12)
Plus LDL-P 1.0 0.84 (0.61–1.16)
Plus HDL-C 1.0 0.84 (0.60–1.16)
Plus HDL-CLDL-P 1.0 0.89 (0.64–1.23)
Plus HDL-C, LDL-P, LDL-C, TG 1.0 0.82 (0.58–1.14)
*1 SD  15 mg/dl for HDL-C and 6.64 mol/l for HDL-P. †Basic model and all substantial mode
CHD  coronary heart disease; CI  confidence intervals; HR  hazard ratios; TG  triglycerideand atherosclerotic cardiovascular risk).Acknowledgments
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